Takeda Pharmaceutical Company Limit ed
FDA inspection history in Hikari, Japan, 2023
- 1
- Form 483
Every document, by year
- Form 483
2023: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2023One Form 483, at Hikari, Japan.
Cited most
Across all Takeda Pharmaceutical Company Limit ed observations on file
- 21 CFR 211.192Production record review2
- 21 CFR 211.165Testing and release for distribution1
- 21 CFR 211.42Design and construction features1
The complete Takeda Pharmaceutical Company Limit ed file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Hikari, Japan
One Form 483 · 2023 · 4 observations
Latest: Form 483, Nov 6, 2023 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2023-11-06 | 483 Form 483 | Hikari, Japan | 4 | $99 |
Investigators on these documents
FEI number 3004664 · most recent document Nov 6, 2023
About Takeda Pharmaceutical Company Limit ed
How many FDA Form 483s has Takeda Pharmaceutical Company Limit ed received?
FDA Intel has 1 Form 483 on file for Takeda Pharmaceutical Company Limit ed; the most recent is dated Nov 6, 2023.
When was Takeda Pharmaceutical Company Limit ed last inspected by FDA?
The most recent FDA inspection document on file for Takeda Pharmaceutical Company Limit ed is a Form 483 dated Nov 6, 2023, for the site in Hikari, Japan.
What did FDA cite at Takeda Pharmaceutical Company Limit ed?
The regulations cited most in the observations on file for Takeda Pharmaceutical Company Limit ed are 21 CFR 211.192 (Production record review), 2 times; 21 CFR 211.165 (Testing and release for distribution), 1 time; 21 CFR 211.42 (Design and construction features), 1 time.